Guidelines for follow-up of women at high risk for inherited breast cancer:: Consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer

被引:34
作者
Moller, P [1 ]
Evans, G
Haites, N
Vasen, H
Reis, MM
Anderson, E
Apold, J
Hodgson, S
Eccles, D
Olsson, H
Stoppa-Lyonnet, D
Chang-Claude, J
Morrison, PJ
Bevilacqua, G
Heimdal, K
Mæhle, L
Lalloo, F
Gregory, H
Preece, P
Borg, Å
Nevin, NC
Caligo, M
Steel, CM
机构
[1] Norwegian Radium Hosp, Unit Med Genet, N-0310 Oslo, Norway
[2] Christie Hosp NHS Trust, Ctr Canc Epidemiol, Family Hist Clin, Manchester M20 4QL, Lancs, England
[3] Univ Aberdeen, Dept Med Genet, Aberdeen AB25 2ZD, Scotland
[4] Leiden Univ Hosp, Netherlands Fdn Detect Hereditary Tumours, NL-2333 AA Leiden, Netherlands
[5] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg, Dundee DD1 9SY, Scotland
[6] Univ Dundee, Ninewells Hosp & Med Sch, Dept Genet, Dundee DD1 9SY, Scotland
[7] Breast Screening Ctr, Family Hist Clin, Edinburgh EH11 2JL, Midlothian, Scotland
[8] Haukeland Hosp, Dept Med Genet, N-5521 Bergen, Norway
[9] Guys Hosp, Div Med & Mol Genet, London SE1 9RT, England
[10] Princess Ann Hosp, Dept Human Genet, Southampton SO16 5YA, Hants, England
[11] Univ Lund Hosp, Dept Oncol, SE-22185 Lund, Sweden
[12] Inst Curie, Unite Genet Oncol, F-75231 Paris 05, France
[13] German Canc Res Ctr, Div Epidemiol, D-69120 Heidelberg, Germany
[14] Belfast City Hosp Trust, No Ireland Reg Med Genet Ctr, Belfast BT9 7AB, Antrim, North Ireland
[15] Univ Pisa, Inst Pathol, I-56126 Pisa, Italy
关键词
D O I
10.1155/1999/920109
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Protocols for activity aiming at early diagnosis and treatment of inherited breast or breast-ovarian cancer have been reported. Available reports on outcome of such programmes are; considered here. It is concluded that the ongoing activities should continue with minor modifications. Direct evidence of a survival benefit from breast and ovarian screening is not yet available. On the basis of expert opinion and preliminary results from intervention programmes indicating good detection rates for early breast cancers and 5-year survival concordant with early diagnosis, we propose that women at high risk for inherited breast cancer be offered genetic counselling, education in 'breast awareness' and annual mammography and clinical expert examination from around 30 years of age. Mammography every second year may be sufficient from 60 years on. BRCA1 mutation carriers may benefit from more frequent examinations and cancer risk may be reduced by oophorectomy before 40-50 years of age. We strongly advocate that all activities should be organized as multicentre studies subjected to continuous evaluation to measure the effects of the interventions on long-term mortality, to match management options more precisely to individual risks and to prepare the ground for studies on chemoprevention.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 24 条
[1]   BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations [J].
Borg, Å ;
Dorum, A ;
Heimdal, K ;
Mæhle, L ;
Hovig, E ;
Moller, P .
DISEASE MARKERS, 1999, 15 (1-3) :79-84
[2]  
CHEN KTK, 1985, OBSTET GYNECOL, V66, pS93
[3]   Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer [J].
Dorum, A ;
Heimdal, K ;
Hovig, E ;
Inganäs, M ;
Moller, P .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (03) :671-679
[4]  
DORUM A, IN PRESS ACTA OBST G
[5]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[6]   Management of hereditary breast cancer [J].
Eccles, DM ;
Simmonds, P ;
Goddard, J ;
Coultas, M ;
Lalloo, F ;
Evans, G ;
Haites, N .
DISEASE MARKERS, 1999, 15 (1-3) :187-189
[7]  
ECCLES DM, UNPUB GUIDELINES MAN
[8]   Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee [J].
Eisinger, F ;
Alby, N ;
Bremond, A ;
Dauplat, J ;
Espie, M ;
Janiaud, P ;
Kuttenn, F ;
Lebrun, JP ;
Lefranc, JP ;
Pierret, J ;
Sobol, H ;
Stoppa-Lyonnet, D ;
Thouvenin, D ;
Tristant, H ;
Feingold, J .
ANNALS OF ONCOLOGY, 1998, 9 (09) :939-950
[9]   Utilisation of prophylactic mastectomy in 10 European centers [J].
Evans, DGR ;
Anderson, E ;
Lalloo, F ;
Vasen, H ;
Beckmann, M ;
Eccles, D ;
Hodgson, S ;
Moller, P ;
Chang-Claude, J ;
Morrison, P ;
Stoppa-Lyonnet, D ;
Steel, M ;
Haites, N .
DISEASE MARKERS, 1999, 15 (1-3) :148-151
[10]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689